Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Doriana Gramegna, M.D.

Concepts (60)

Back to Profile
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Myeloproliferative Disorders120225910.580 Why?
Neoplasms, Second Primary120229850.530 Why?
Hematopoietic Stem Cell Transplantation3202251350.340 Why?
Invasive Pulmonary Aspergillosis12019120.190 Why?
Transplantation, Autologous2202220920.190 Why?
Core Binding Factor Alpha 2 Subunit120223480.190 Why?
Hydrazines120192270.160 Why?
Benzoates120192400.160 Why?
Leukemia, Promyelocytic, Acute120182380.160 Why?
Sarcopenia120213040.160 Why?
Thrombopoietin120192200.160 Why?
Fusion Proteins, bcr-abl120194270.150 Why?
Anemia, Hemolytic, Autoimmune120181450.150 Why?
Purpura, Thrombocytopenic, Idiopathic120192170.140 Why?
Receptors, Fc120195620.140 Why?
Leukemia, Myeloid, Acute2202032810.130 Why?
Leukemia, Myelogenous, Chronic, BCR-ABL Positive120196790.130 Why?
Hodgkin Disease1202114120.120 Why?
Hematopoiesis1202220150.110 Why?
Lymphoma, Large B-Cell, Diffuse1202112640.110 Why?
Bone Marrow Cells1201925960.100 Why?
Precursor Cell Lymphoblastic Leukemia-Lymphoma1201914540.100 Why?
Recombinant Fusion Proteins1201938780.100 Why?
Pyrazoles1201919540.090 Why?
Antineoplastic Combined Chemotherapy Protocols22020112530.060 Why?
Gene Expression Regulation, Neoplastic1201986380.060 Why?
Protein Kinase Inhibitors1201954050.060 Why?
Prognosis52021289190.060 Why?
Daunorubicin120201520.050 Why?
Cytarabine120206890.040 Why?
Mutation12022292620.040 Why?
Survival Analysis22020105070.040 Why?
Antifungal Agents120197100.030 Why?
Workflow120188030.030 Why?
Humans820227088430.030 Why?
Transplantation, Homologous1201948310.020 Why?
Drug Administration Schedule1201950450.020 Why?
Aged520211614880.020 Why?
Middle Aged520212137520.020 Why?
Combined Modality Therapy1202088960.020 Why?
Academic Medical Centers1201927790.020 Why?
Disease-Free Survival1201970260.020 Why?
Retrospective Studies32021714830.020 Why?
Disease Management1201825360.020 Why?
Molecular Targeted Therapy1201928780.020 Why?
Dose-Response Relationship, Drug12019112390.020 Why?
Male520213495240.020 Why?
Multivariate Analysis12019124470.020 Why?
Female520213752050.020 Why?
Proportional Hazards Models12019122920.020 Why?
Young Adult22020559400.020 Why?
Treatment Outcome22020619320.010 Why?
Aged, 80 and over22019581840.010 Why?
Adult320202110410.010 Why?
Neoplasm Recurrence, Local1201888770.010 Why?
Follow-Up Studies12019390380.010 Why?
Cohort Studies12019392920.010 Why?
Tomography, X-Ray Computed12019203080.010 Why?
Prospective Studies12018505970.010 Why?
Adolescent12019847180.010 Why?
Gramegna's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (60)
Explore
_
Co-Authors (12)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
© 2023 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.